Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권기환 | * |
dc.contributor.author | 편욱범 | * |
dc.date.accessioned | 2023-07-31T16:31:16Z | - |
dc.date.available | 2023-07-31T16:31:16Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 1524-6175 | * |
dc.identifier.other | OAK-33512 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/265345 | - |
dc.description.abstract | We compared the efficacy and safety of third-standard-dose triple and third-standard-dose dual antihypertensive combination therapies in patients with mild to moderate hypertension. This was a phase II multicenter, randomized, double-blind, parallel-group trial. After a 4-week placebo run-in period, 245 participants were randomized to the third-dose triple combination (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg) or third-dose dual combination (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg, LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg, AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg) therapy groups and followed up for 8 weeks. The mean systolic blood pressure (BP) reduction was -18.3 ± 13.2, -13.0 ± 13.3, -16.3 ± 12.4, and -13.8 ± 13.2 mmHg in the ALC, AL, LC, and AC groups, respectively. The ALC group showed significant systolic BP reduction compared to the AL and AC groups at weeks 4 (P =.010 and P =.018, respectively) and 8 (P =.017 and P =.036, respectively). At week 4, the proportion of systolic BP responders was significantly higher in the ALC group (42.6%) than in the AL (22.0%), LC (23.3%), and AC (27.1%) groups (P =.013, P =.021, and P =.045, respectively). At week 8, the proportion of systolic and diastolic BP responders was significantly higher in the ALC group (59.7%) than in the AL (39.3%) and AC (42.4%) groups (P =.022 and P =.049, respectively) at week 8. Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension. © 2023 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC. | * |
dc.language | English | * |
dc.publisher | John Wiley and Sons Inc | * |
dc.subject | combination therapy | * |
dc.subject | hypertension | * |
dc.subject | low-dose | * |
dc.title | Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 25 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 429 | * |
dc.relation.lastpage | 439 | * |
dc.relation.journaltitle | Journal of Clinical Hypertension | * |
dc.identifier.doi | 10.1111/jch.14656 | * |
dc.identifier.wosid | WOS:000989811300001 | * |
dc.identifier.scopusid | 2-s2.0-85153631049 | * |
dc.author.google | Sung K.-C. | * |
dc.author.google | Hong S.J. | * |
dc.author.google | Rhee M.-Y. | * |
dc.author.google | Jeong M.-H. | * |
dc.author.google | Kim D.-H. | * |
dc.author.google | Lim S.-W. | * |
dc.author.google | Park K. | * |
dc.author.google | Lee J.B. | * |
dc.author.google | Kim S.-Y. | * |
dc.author.google | Cho J.-M. | * |
dc.author.google | Cho G.-Y. | * |
dc.author.google | Heo J.-H. | * |
dc.author.google | Kim S.-H. | * |
dc.author.google | Lee H.-Y. | * |
dc.author.google | Kim W. | * |
dc.author.google | Cho D.-K. | * |
dc.author.google | Park S. | * |
dc.author.google | Shin J. | * |
dc.author.google | Pyun W.-B. | * |
dc.author.google | Kwon K. | * |
dc.author.google | Rha S.-W. | * |
dc.author.google | Jung J.-A. | * |
dc.contributor.scopusid | 권기환(57203037966) | * |
dc.contributor.scopusid | 편욱범(6508352922) | * |
dc.date.modifydate | 20240123092816 | * |